LAG-3 was proposed as a candidate for combination therapy with PD-1 blockade in adult cHL to restore T-cell function more efficiently than either one alone (30), whereas in pediatric patients, the scenario is quite unexplored. Here, SNCA is linked to classic Hodgkin lymphoma.